Akero Therapeutics, Inc. (AKRO)
Largest Insider Buys in Sector
AKRO Stock Price History Chart
AKRO Stock Performance
About Akero Therapeutics, Inc.
Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. It also conducts a Phase 2a clinical trial, the BALANCED study, to evaluate EFX in the treatment of biopsy-confirmed NASH …
Insider Activity of Akero Therapeutics, Inc.
Over the last 12 months, insiders at Akero Therapeutics, Inc. have bought $3.68M and sold $23.72M worth of Akero Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Akero Therapeutics, Inc. have bought $23.17M and sold $45.53M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Graham G. Walmsley (director) — $11.03M.
The last purchase of 100,000 shares for transaction amount of $1.98M was made by Graham G. Walmsley (director) on 2023‑12‑08.
List of Insider Buy and Sell Transactions, Akero Therapeutics, Inc.
| 2024-11-01 | Sale | President and CEO | 108,366 0.1532% | $31.73 | $3.44M | -0.87% | ||
| 2024-11-01 | Sale | Chief Operating Officer | 50,716 0.0713% | $31.57 | $1.6M | -0.87% | ||
| 2024-11-01 | Sale | Chief Development Officer | 15,485 0.0225% | $32.62 | $505,105 | -0.87% | ||
| 2024-10-30 | Sale | Chief Development Officer | 4,515 0.0069% | $32.53 | $146,855 | +4.40% | ||
| 2024-10-18 | Sale | President and CEO | 63,539 0.0924% | $31.53 | $2M | +0.27% | ||
| 2024-10-17 | Sale | President and CEO | 3,103 0.0045% | $31.12 | $96,559 | +1.33% | ||
| 2024-10-16 | Sale | President and CEO | 24,992 0.0382% | $31.14 | $778,151 | +0.05% | ||
| 2024-10-15 | Sale | Chief Development Officer | 14,825 0.0222% | $30.50 | $452,233 | +3.74% | ||
| 2024-10-14 | Sale | Chief Operating Officer | 40,000 0.0592% | $30.15 | $1.21M | +3.22% | ||
| 2024-10-14 | Sale | Chief Development Officer | 6,136 0.009% | $30.03 | $184,258 | +3.22% | ||
| 2024-10-01 | Sale | Chief Operating Officer | 10,000 0.0138% | $28.18 | $281,770 | +4.09% | ||
| 2024-09-20 | Sale | Chief Development Officer | 5,500 0.0078% | $27.65 | $152,086 | +5.52% | ||
| 2024-09-18 | Sale | Chief Development Officer | 3,871 0.0057% | $27.56 | $106,685 | +8.35% | ||
| 2024-09-17 | Sale | Chief Development Officer | 2,037 0.003% | $27.55 | $56,115 | +9.40% | ||
| 2024-09-16 | Sale | Chief Development Officer | 2,485 0.0037% | $27.52 | $68,375 | +8.63% | ||
| 2024-09-10 | Sale | President and CEO | 1,738 0.0025% | $26.18 | $45,501 | +11.73% | ||
| 2024-09-10 | Sale | Chief Operating Officer | 568 0.0008% | $26.18 | $14,870 | +11.73% | ||
| 2024-09-10 | Sale | Chief Scientific Officer | 537 0.0008% | $26.18 | $14,059 | +11.73% | ||
| 2024-09-10 | Sale | Chief Development Officer | 637 0.0009% | $26.18 | $16,677 | +11.73% | ||
| 2024-09-10 | Sale | Chief Financial Officer | 639 0.0009% | $26.18 | $16,729 | +11.73% |
Insider Historical Profitability
| Graham G. Walmsley | director | 800000 1.1522% | $35.55 | 9 | 0 | +9.4% |
| Apple Tree Partners IV, L.P. | 10 percent owner | 5830203 8.3971% | $35.55 | 2 | 0 | <0.0001% |
| Versant Venture Capital VI, L.P. | 10 percent owner | 3092698 4.4544% | $35.55 | 1 | 22 | +13.18% |
| venBio Global Strategic Fund II L.P. | 10 percent owner | 3033552 4.3692% | $35.55 | 1 | 25 | +13.18% |
| Atlas Venture Fund XI, L.P. | 10 percent owner | 505099 0.7275% | $35.55 | 1 | 0 | +13.18% |
Institutional Investor Ownership
| Janus Henderson | $154.59M | 8.85 | 6.12M | +42.16% | +$45.85M | 0.08 | |
| RTW Investments, LP | $137.21M | 7.86 | 5.43M | +51.19% | +$46.46M | 2.06 | |
| General Atlantic | $132.21M | 7.57 | 5.23M | +193.1% | +$87.1M | 3.44 | |
| Wellington Management Company | $131.69M | 7.54 | 5.21M | +80.89% | +$58.89M | 0.02 | |
| BlackRock | $123.59M | 7.08 | 4.89M | +17.03% | +$17.99M | <0.01 |